| This week's sponsor is Premier Research. | | | Placebo Response: A Real Threat to Pain Trials
Rising placebo response rates skew analgesia clinical trial data and limit treatment options for suffering patients. Learn how to manage this pain point in analgesia trials with our free eBook. Premier Research. It's what we do. Best. |
Today's Rundown Lilly pays AC Immune $81M upfront for preclinical Alzheimer’s drug NASH-focused Akero Therapeutics adds another $70M to the bank Casma names Third Rock venture partner as COO GenSight rebuilds its case for LHON gene therapy, eyeing filing next year Roche to develop new dMMR pan-cancer test for Merck’s Keytruda immunotherapy FDA clears first xenotransplantation trial of skin cells derived from genetically engineered pigs Featured Story | | | Wednesday, December 12, 2018 Eli Lilly has paid CHF 80 million ($81 million) upfront for the worldwide rights to AC Immune’s tau aggregation inhibitors in Alzheimer’s disease. The deal gives Lilly ownership of a small molecule that has inhibited tau aggregation in preclinical models. |
|
|
Top Stories Wednesday, December 12, 2018 The company has reeled in $70 million that will push its lead asset, a treatment for nonalcoholic steatohepatitis licensed from Amgen, through phase 2. Akero will also build out its metabolic disease pipeline and boost its manufacturing capabilities. Wednesday, December 12, 2018 Casma Therapeutics has named Third Rock Ventures’ Frank Gentile as its chief operating officer. The appointment means Gentile will commit full time to the autophagy startup he helped get off the ground. Wednesday, December 12, 2018 GenSight Biologics has reported new data from its phase 3 program for GS010, its gene therapy for an ultrarare eye disease, sparking another uptick in its share price. Wednesday, December 12, 2018 If you can’t beat 'em, join 'em: Roche is teaming up with its immuno-oncology competitor Merck & Co. to develop a pan-cancer companion diagnostic test for its Keytruda therapy aimed at detecting the mismatch repair deficiency biomarker, or dMMR, in solid tumors regardless of their location. Wednesday, December 12, 2018 The FDA has cleared XenoTherapeutics to begin a first-of-its-kind human clinical trial that uses topically applied live skin cells derived from genetically engineered pigs as a treatment for severe burns. Resources Sponsored by: Veeva Learn how to spot an imposter with an integrated suite vs. one that’s unified. Read this whitepaper to learn more. Sponsored by: Patheon, part of Thermo Fisher Scientific Read this whitepaper to learn how the biologics market is quickly evolving and how these changes pose several risks to a molecule’s success. Sponsored by: Coupa Software Learn how Becton Dickinson implemented Coupa to create an easy-to-use purchase to pay process that increased efficiency across the organization. Sponsored by: Almac Diagnostic Services, part of the Almac Group Download the whitepaper to learn more. Sponsored by: Reprints Desk, Inc. Learn how to fast-track your research workflows! Sponsored by: Veeva Industry Research: Read the 2018 Unified Clinical Operations Report to find out how pharmas and CROs are evolving clinical trial processes. Sponsored by: Applied BioMath This on-demand webinar introduces a quantitative systems pharmacology (QSP) model of targeted anabolic growth factors for intra-articular injection for the treatment of diseased joints. Sponsored by: Oracle Health Sciences New research reveals more than 50% of clinical data management professionals surveyed, are not confident in the quality and completeness of their clinical trial data. Sponsored by: Veradigm New Case Study – Leveraging Real-World Evidence From EHR to Assess Migraine Management Sponsored by: Signals Analytics What does data tell us about the future of cell & gene therapy? Sponsored by: Outer Edge Technology Outer Edge Technology specializes in designing and managing regulated cloud-based infrastructures for the Life Sciences Industry – typically leveraging the AWS and Microsoft Azure platforms. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. Drug Approval, Manufacturing Quality & Regulation 2018 | Online FierceBiotech Executive Breakfast at the J.P. Morgan Healthcare Conference 2019 January 8, 2019 | The Fairmont Hotel | San Francisco, CA Phacilitate Leaders World 2019 January 22-25, 2019 I Hyatt Regency, Miami Asia-Pacific Compliance Training for Life Sciences Professionals March 4-7, 2019 | Singapore | 